The latest announcement is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC has announced the purchase and cancellation of 581,885 ordinary shares as part of its share buyback programme. This move is expected to impact the company’s share capital and voting rights, with the number of ordinary shares with voting rights now standing at 9,034,907,985. The buyback is part of Haleon’s strategy to manage its capital structure and enhance shareholder value.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on improving everyday health with a portfolio that includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements. The company is known for its trusted brands such as Advil, Sensodyne, Panadol, and Centrum, which are built on innovation and a deep understanding of consumer needs.
YTD Price Performance: 3.31%
Average Trading Volume: 27,838,266
Technical Sentiment Signal: Sell
Current Market Cap: £35.23B
For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.